In a 2023 study, people taking 2.4 mg of semaglutide each week were nearly twice as likely to see NASH go away, without their liver scarring getting worse, compared to those on a placebo
(Several experts have urged caution against use of counterfeit semaglutide products promoted to yield this weight-loss effect, as some of these have reportedly caused hospitalization among some consumers.) On March 8, 2024, the FDA had approved Wegovy for use by people with cardiovascular disease to reduce the risk of heart attack and stroke, opening the door to the Medicare approval process
Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice
Potential areas of interest include type 2 diabetes, obesity, cardiovascular health, and metabolic improvement
Do not freeze it freezing damages the peptide
CD45 BUV395 (BD Biosciences, clone 30-F11, 564279, 1:2000)